title: Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder.
abstract: Pagoclone is a cyclopyrrolone that is believed to act as a partial agonist at the gamma-aminobutyric acid (GABA)-A/benzodiazepine (BDZ) receptor. In theory, such partial agonists should be anxiolytic but lack the adverse side-effects of sedation, tolerance and withdrawal associated with full GABA-A/BDZ agonists. The objective of the randomized double-blind crossover study was to assess whether pagoclone was an effective anti-panic agent and also to assess its side-effect profile. Patients recruited had a diagnosis of Panic Disorder (DSM-IV) with at least one panic attack per week. Following a 2-week screening period, patients entered a 6-week trial consisting of two 2-week treatment periods, each followed by a 1-week washout. Patients were randomly assigned to receive either pagoclone 0.1 mg t.d.s. or placebo on their first treatment period and the converse on their second. The primary measure was daily panic attack dairy. Fourteen patients completed the study, the mean number of panic attacks during screening was 5.8+/-0.8 (SEM), this fell to 3.6+/-0.5 during treatment with pagoclone (p = 0.05) and 4.3+/-0.8 with placebo (p = 0.14). There was no significant difference on direct comparison of pagoclone with placebo or in any of the secondary measures (including Rickels withdrawal scale) or the adverse event profiles. The study provides preliminary evidence that pagoclone has anxiolytic properties in the absence of typical BDZ side-effects. This is consistent with its theoretical mode of action as a partial agonist at the GABA(A)/BDZ receptor.
authors.affiliation: Psychopharmacology Unit, School of Medical Sciences, University of Bristol, UK. john.j.sandford@ukgateway.net
authors.forename: J J
authors.initials: JJ
authors.lastname: Sandford
authors.forename: S
authors.initials: S
authors.lastname: Forshall
authors.forename: C
authors.initials: C
authors.lastname: Bell
authors.forename: S
authors.initials: S
authors.lastname: Argyropoulos
authors.forename: A
authors.initials: A
authors.lastname: Rich
authors.forename: K J
authors.initials: KJ
authors.lastname: D'Orlando
authors.forename: R E
authors.initials: RE
authors.lastname: Gammans
authors.forename: D J
authors.initials: DJ
authors.lastname: Nutt
mesh_terms: D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy* / Q000523:psychology; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D018755:GABA Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D009287:Naphthyridines / Q000009:adverse effects / Q000627:therapeutic use; D016584:Panic Disorder / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D018755:GABA Agonists; D054833:Isoindoles; D009287:Naphthyridines; C447412:pagoclone